Off-Label Pacira Warning Letter Dropped From FDA's Website
This article was originally published in The Gray Sheet
Executive Summary
FDA has apparently taken down a warning letter from its website describing off-label marketing violations by Pacira Pharmaceuticals, a drug company that is suing the agency over First Amendment free speech rights. The agency’s response in the lawsuit is due this month.